October 2000
OptiNose founded in Oslo, Norway

December 2000
OptiNose wins the Venture Cup Prize, an annual business plan competition that works to discover new entrepreneurs and facilitate the realization of their business ideas

November 2001
Seed investment received, basic prototype developed

November 2001
First clinical study conducted focusing on proving the hypothesis that bi-directional delivery is achieved and that lung deposition is avoided

November 2002
Clinical trial conducted with influenza vaccine comparing four different administration devices – OptiNose device, conventional nasal spray, nasal drops and mouth spray

December 2002
Clinical trial conducted with diphtheria vaccine comparing OptiNose device and conventional spray pump

Copyright © 2011 OptiNose US Inc.
December 2002
OptiNose receives first investment from Entrepreneurs Fund

November 2003
Clinical trial conducted with midazolam comparing OptiNose device with traditional nasal spray and IV

April 2004
United Kingdom office established

September 2004
Data on bi-directional nasal delivery prevent lung deposition published in Journal of Aerosol Medicine

December 2005
OptiNose receives a $15 million investment from New York-based venture capital firm WFD Ventures

March 2006
Data on significantly improved dose deposition of the OptiNose device compared with conventional nasal spray published in Laryngoscope
March 2006
Clinical trial results of influenza vaccine and OptiNose device published in Scandinavian Journal of Immunology

May 2006
Phase I clinical trials for nasal polyps with fluticasone and OptiNose device conducted

July 2006
Phase I clinical trials for migraine headache with sumatriptan and OptiNose device conducted

October 2006
Clinical trial results of intranasal midazolam with OptiNose device published in Journal of Pharmacy and Pharmacology

April 2007
Phase II clinical trials for migraine headache with sumatriptan and OptiNose device conducted

May 2007
Phase II clinical trials for nasal polyps with fluticasone and OptiNose device conducted
**September 2007**
Phase II clinical trials for refractory chronic rhinosinusitis with fluticasone and OptiNose device conducted

**March 2008**
Phase I clinical trials with human insulin and OptiNose device conducted

**June 2009**
Phase I clinical trials for migraine headache with sumatriptan and OptiNose device published in Journal of Pharmacy and Pharmacology

**September 2009**
Method paper highlighting gammascintiggraphy deposition in the human nose published in Nuclear Communication Medicine

**December 2009**
Phase II clinical trial results for nasal polyps with fluticasone and OptiNose device published in Rhinology

**March 2010**
Phase II clinical trial results for migraine headache with sumatriptan and OptiNose device published in Cephalalgia
June 2010
OptiNose receives a $48.5 million investment from New York-based private equity firm Avista Capital Partners.

June 2010
OptiNose reincorporates its business in the United States and moved its headquarters from Oslo, Norway to Yardley, PA.

June 2010
Peter Miller named President and Chief Executive Officer of OptiNose.

August 2010
Phase II sub-group analysis in nasal polyps with fluticasone and OptiNose device published in American Journal of Rhinology and Allergy.

September 2010
Phase II clinical trials results for refractory chronic rhinosinusitis with fluticasone and OptiNose device published in Rhinology.